Ultromics

Ultromics, a spun-out from the Oxford University, is a maker of an AI-supported cardiac-decision-support tool that is championing a new era of medical diagnosis through innovating automated tools to support physicians in the detection of cardiovascular disease.

Ultromics provides autonomous echocardiography analysis, empowering physicians to make fast, accurate diagnostic decisions.

Ultromics was founded in 2017 by Ross Upton and Professor Paul Leeson. The company is headquartered in Oxford, Oxfordshire, United Kingdom.

 

Ultromics provides automated software powered by AI that allows clinicians to make fast, accurate decisions when using ultrasound images to diagnose cardiovascular disease.

 

Ultromics' The EchoGo Core and EchoGo Pro platforms deliver accurate assessments of heart function that support the diagnosis of coronary artery disease, heart failure and amyloidosis.

 

Ultromics' EchoGo Core and EchoGo Pro are already being used and validated by several organizations, including Mayo Clinic and the Oregon Health and Science University.

 

Ultromics is backed by Oxford Sciences Innovation, Mayo Clinic, Optum Ventures, GV, Blue Venture Fund, Neptune, RT Ventures, GT Healthcare, Woodford Investment Management and others. The company raised $33M in Series B round on Aug 16, 2021. This brings Ultromics' total funding to $59M to date.

 

 

  • Year founded: 2017
  • Funding Info: $59M over 4 Rounds (Latest Funding Type: Series B)
  • Yearly Revenue: NA
  • Employee Size: 51-200
  • Business Valuation: NA
  • City/Town: Oxford
  • State: Oxfordshire
  • Country: United Kingdom
Related businesses